bioAffinity Technologies Joins National Lung Cancer Roundtable

PUBLISHED ON October 11, 2019

OCTOBER 11, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer Society’s National Lung Cancer Roundtable (NLCRT), a collaborative whose membership is focused on reducing both the incidence of lung cancer and mortality rates from the disease.

read more

bioAffinity Technologies Announces Members of its Scientific and Medical Advisory Board

PUBLISHED ON October 2, 2019

OCTOBER 2, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the members of its Scientific and Medical Advisory (SMA) Board who will provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics, including CyPath® Lung, a non-invasive test for the early detection of lung cancer.

read more

SA has More Room for Women in Bioscience C-suite

PUBLISHED ON September 6, 2019

San Antonio Business Journal (August 29, 2019) While there is acknowledgment that women have made progress in their climb to executive-level positions in San Antonio's bioscience industry and may find fewer roadblocks here than in some markets, some of the local women leaders in the industry said there is a need to bust a wider hole through the glass ceiling.

read more

bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair

PUBLISHED ON March 12, 2019

San Antonio, TX (March 12, 2019)  bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics and therapeutics, including CyPath® Lung.

read more

bioAffinity Technologies Selected as Finalist for Cancer Innovation Award

PUBLISHED ON March 6, 2019

San Antonio, TX (March 6, 2019) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation Award recognizes groundbreaking work to advance the prevention and management of cancer.

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.

 

www.thehealthcell.org/sitepage/state-of-the-industry/